Zobrazeno 1 - 10
of 177
pro vyhledávání: '"David A. Tice"'
Autor:
Yoshimi Endo Greer, Samuel F. Gilbert, Brunilde Gril, Rajesh Narwal, Danielle L. Peacock Brooks, David A. Tice, Patricia S. Steeg, Stanley Lipkowitz
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-17 (2019)
Abstract Background TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by activating death receptors (DR) 4 and 5 with little toxicity again
Externí odkaz:
https://doaj.org/article/75aaa9bb29a348af824baf7968e72d6a
Autor:
Kelsey A. Finkel, Kristy A. Warner, Samuel Kerk, Carol R. Bradford, Scott A. McLean, Mark E. Prince, Haihong Zhong, Elaine M. Hurt, Robert E. Hollingsworth, Max S. Wicha, David A. Tice, Jacques E. Nör
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 5, Pp 273-281 (2016)
Head and neck squamous cell carcinomas (HNSCC) exhibit a small population of uniquely tumorigenic cancer stem cells (CSC) endowed with self-renewal and multipotency. We have recently shown that IL-6 enhances the survival and tumorigenic potential of
Externí odkaz:
https://doaj.org/article/37e6b16252af4215b4803b703ad423bc
Autor:
Nabendu Pore, Sanjoo Jalla, Zheng Liu, Brandon Higgs, Claudio Sorio, Aldo Scarpa, Robert Hollingsworth, David A. Tice, Emil Michelotti
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 17, Iss 6, Pp 473-480 (2015)
Reprogramming of energy metabolism is one of the emerging hallmarks of cancer. Up-regulation of energy metabolism pathways fuels cell growth and division, a key characteristic of neoplastic disease, and can lead to dependency on specific metabolic pa
Externí odkaz:
https://doaj.org/article/a83f7e43caf041d6865328ba74b733bc
Autor:
Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Andrew J. Pierce, Melissa Damschroder, Brandy Wilkinson, Jay Friedman, Changshou Gao, Xiaofang Jin, Jenny Heidbrink-Thompson, Ching Ching Leow, Ray Rothstein, Kevin Schifferli, Qun Du, Li Cheng, Ravinder Tammali, Linda Xu, Dave Stewart, Jon Chesebrough, Darrin Sabol, Jonathan Rios-Doria
Supplementary Figures 1-14; Supplementary Tables 1-3. Supplementary Figure 1. Lead antibody 80PH3 is a potent inhibitor of recombinant ADAM17 Supplementary Figure 2. 80PH3 is not a potent inhibitor of cellular ADAM17 Supplementary Figure 3. MEDI3622
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ed06737d64a6e14f0434751d7b92c6
https://doi.org/10.1158/1535-7163.22502130
https://doi.org/10.1158/1535-7163.22502130
Autor:
David A. Tice, Robert E. Hollingsworth, Ronald Herbst, Bahija Jallal, Philipp Steiner, Ping Tsui, Partha Chowdhury, Chunning Yang, Leslie Wetzel, Ray Rothstein, Hong Chen, Ravinder Tammali, Krista Kinneer, Kevin Schifferli, Rosa A. Carrasco, Zhan Xiao
HER3/ERBB3 is a kinase-deficient member of the EGFR family receptor tyrosine kinases (RTK) that is broadly expressed and activated in human cancers. HER3 is a compelling cancer target due to its important role in activation of the oncogenic PI3K/AKT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcc96583b01d461e7fb0468a7a88fa35
https://doi.org/10.1158/1535-7163.c.6538702.v1
https://doi.org/10.1158/1535-7163.c.6538702.v1
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these agents:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2efa1fb2eca5731e15fb0928e1e7b7
https://doi.org/10.1158/1535-7163.c.6543438.v1
https://doi.org/10.1158/1535-7163.c.6543438.v1
Autor:
Adeela Kamal, Ronald Herbst, Robert E. Hollingsworth, David A. Tice, Philip W. Howard, Keven Huang, Mary Jane Hinrichs, Elaine M. Hurt, Haihong Zhong, Marlon Rebelatto, Sanjoo Jalla, Lilian van Vlerken-Ysla, Shannon Breen, Leslie Wetzel, Cui Chen, Linda Xu, Patrick Strout, Martin Korade, Allison M. Marrero, Shenlan Mao, Francois D'Hooge, Ryan Fleming, Jelena Jovanovic, David Bannister, Leeanne Lewis, Rose Marwood, Dorin Toader, Nazzareno Dimasi, Christopher Lloyd, Jay Harper
Supplementary Figure S1. Comparable internalization rates for 5T4_0108 and the 5T4-Tub ADC;Supplementary Figure S2. Affinity optimization improves in vitro cytotoxicity of a 5T4-ADC;Supplementary Figure S3. Induction of apoptosis by 5T4-PBD and 5T4-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de526dbdf0be492e85149344521acac5
https://doi.org/10.1158/1535-7163.22508511
https://doi.org/10.1158/1535-7163.22508511
Autor:
Jay Harper, Mark Cobbold, David A. Tice, Philip W. Howard, Ronald Herbst, Herren Wu, Changshou Gao, Luke A. Masterson, Kimberly Cook, Kathryn Pugh, Susan Wilson, Nazzareno Dimasi, Jens-Oliver Koopmann, Sonja Hess, Ryan Fleming, Sandrina Phipps, Allison M. Barrett, Hong Chen, Andrew Garcia, Gina D’Angelo, Wen Yu, Raghothama Chaerkady, Shenlan Mao
The addition of the ATR inhibitor, AZD6738, did not show synergistic cytotoxicity with SG3199 or ADCs in parental MDA-MB-361 cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63d95af0ffa8c167232f6d1a26846154
https://doi.org/10.1158/1535-7163.22521297.v1
https://doi.org/10.1158/1535-7163.22521297.v1
Autor:
Manuel Baca, David A. Tice, Herren Wu, Ching Ching Leow, Ivan Inigo, Zhan Xiao, Rosa Carrasco, Kristen Lekstrom, Hui Feng, Lin Wang, Luba Grinberg, Jeffery S. Swers
PDF file - 95K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d684f33cb4e97e6f53886e3f0b909e7
https://doi.org/10.1158/1535-7163.22500496
https://doi.org/10.1158/1535-7163.22500496
Autor:
David A. Tice, Robert E. Hollingsworth, Ronald Herbst, Bahija Jallal, Philipp Steiner, Ping Tsui, Partha Chowdhury, Chunning Yang, Leslie Wetzel, Ray Rothstein, Hong Chen, Ravinder Tammali, Krista Kinneer, Kevin Schifferli, Rosa A. Carrasco, Zhan Xiao
Figure 1: KTN3379 specifically binds to HER3; Figure 2: KTN3379 suppresses cell-growth in HRG-HER3 autocrine cells and HRGinduced VEGF secretion; Figure 3: KTN3379 arrests HER2+ breast cancer cells in G0/G1-phase; Figure 4: KTN3379 is inactive in HER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39380c21c500de7b31d46a26363070fb
https://doi.org/10.1158/1535-7163.22507480.v1
https://doi.org/10.1158/1535-7163.22507480.v1